Abstract:Purpose/Objective(s) Recent research has categorized the genetic make-up of head and neck squamous cell cancers (HNSCC) at initial presentation. However, despite advances in treatment, up to 50% of patients develop a recurrent/metastatic (R/M) disease, with a significant decline in survival at that time. Here, we aim to analyze the genetic composition of patients with R/M HNSCC to establish the most frequent alterations in this population and determine if there are associations with survival. Materials/Methods We performed an IRB-approved retrospective analysis of patients with confirmed recurrences of head and neck cancer after treatment for curative intent. We collected clinical data from one institution's electronic health records. Patients were grouped into cancer locations [oropharynx, oral cavity, hypopharynx, larynx, nasopharynx]. Targeted DNA sequencing of the tumor samples was performed by Tempus. R square analysis was done to compare tumor genetic make-up. Results To date, a total of 44 patients with head and neck cancer recurrences were included in the analysis. 43.5% of patients had oral cavity cancer, and 32.6% of patients had oropharynx cancer. Seventeen patients (39%) were p16 positive. The median age at the time of diagnosis was 62.5 years (range 36-82), and the majority of patients were male (n=28, 64%). Twenty-four patients (54%) had a current or former smoking history. The median overall survival time was 721 days from the date of diagnosis. The median disease-free survival was 198 days. Survival rate of the entire cohort was 27.2% at the time of analysis. The most common mutation seen in the cohort was TP53, which was present in 29 patients (65%) and was associated with worse overall and disease-free survival. TERT and CDKN2A mutations were seen in 16 patients (36%), but were not associated with outcomes in this small sample size. Notably, both TERT and CDKN2A mutations are less common for the primary HNSCC diagnosis. Additional alterations were noted in PIK3CA (found in 20% of patients) and LRP1B (found in 9% of patients); while the former is associated with better overall survival, the latter was strongly associated with worse disease-free survival. Conclusion In the analysis of the R/M HNSCC cases, we identified genomic alterations similar to those found during primary diagnosis. While HNSCC cancers are genetically heterogeneous, alterations in TP53 remain the most commonly noted. R/M HNSCC populations commonly have CDKN2A and TERT mutations that are rarely found in primary diagnosis. In addition, mutations in LRP1B were associated with worse disease-free survival. Further analysis is ongoing to define the correlation between the mutational landscape of our patients and their response to therapy.

The Mutational Spectrum of Squamous-Cell Carcinoma of the Head and Neck: Targetable Genetic Events and Clinical Impact

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

Mutational Profiles of Cutaneous Squamous Cell Carcinomas with Different Patterns of Clinical Aggression from Head and Neck Regions

Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review

Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma

Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity

Development and Validation of Radiomic Signatures of Head and Neck Squamous Cell Carcinoma Molecular Features and Subtypes.

Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer

Clinical update on head and neck cancer: molecular biology and ongoing challenges

Genetic and Expression Profiles of Squamous Cell Carcinoma of the Head and Neck Correlate with Cisplatin Sensitivity and Resistance in Cell Lines and Patients

Immune Profiles in Primary Squamous Cell Carcinoma of the Head and Neck.

Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments

The Mutational and Microenvironmental Landscape of Cutaneous Squamous Cell Carcinoma: A Review

Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas

Where We Stand and What Lies Ahead

Molecular characterization of the evolution of premalignant lesions in the upper aerodigestive tract

Comparing Genomic Landscapes of Oral and Cutaneous Squamous Cell Carcinoma of the Head and Neck: Quest for Novel Diagnostic Markers

Single-cell Genomic Analysis of Head and Neck Squamous Cell Carcinoma

Comprehensive Genomic Review of TCGA Head and Neck Squamous Cell Carcinomas (HNSCC)

Tumor Genomics and the Association with Survival in Recurrent/metastatic Head and Neck Cancer Patients

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma